Your search for sitagliptin returned 76 results
Drug Monograph
JANUMET XR
Sitagliptin, metformin (as HCl) ext-rel; 50mg/500mg, 50mg/1000mg, 100mg/1000mg; tabs.
News
Janumet XR Approved for Type 2 Diabetes
Merck announced that the FDA has approved Janumet XR (sitagliptin/metformin HCl extended-release tablets) for the treatment of type 2 diabetes.
Drugs in the Pipeline
FDA accepts NDA for extended-release Janumet for type 2 diabetes
Merck announced that the New Drug Application (NDA) for its investigational extended-release formulation of Janumet (sitagliptin/metformin HCI) for type 2 diabetes has been accepted for standard review by the FDA.
News
FDA Approves Juvisync, a Combination Drug to Treat Type 2 Diabetes and High Cholesterol
The FDA has approved Juvisync, a fixed-dose combination product containing the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin and the HMG-CoA reductase inhibitor simvastatin.
Drug News
Add-On Sitagliptin vs. Sulphonylurea Compared on Insulin Initiation Risk
For patients with type 2 diabetes mellitus (T2DM) treated with metformin, add-on sitagliptin is associated with a lower risk of insulin initiation than add-on sulphonylurea.
News
Drug Switch Leads to Superior HbA1c Reduction in Sitagliptin vs. Victoza Study
Switching from sitagliptin to Victoza (liraglutide [rDNA origin]; Novo Nordisk), in combination with metformin, showed superior HbA1c reductions vs. continuing with sitagliptin in adults with type 2 diabetes.
News
Is Sitagliptin Effective in Nonalcoholic Fatty Liver Disease?
Sitagliptin was not superior to placebo in reducing liver fat in prediabetic or diabetic patients with nonalcoholic fatty liver disease (NAFLD), according to a study published in the Journal of Hepatology.
